MedPath

Bristol-Myers Squibb Pharma EEIG

🇮🇪Ireland
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

142

CIMA_AEMPS:67
NMPA:37
EMA:30
+1 more agencies

Drug Approvals

Nivolumab injection

Product Name
欧狄沃
Approval Number
国药准字SJ20245001
Approval Date
Oct 14, 2024
NMPA

Deucravacitinib Tablets

Product Name
颂狄多
Approval Number
国药准字HJ20230120
Approval Date
Feb 22, 2024
NMPA

Lenalidomide capsules

Product Name
瑞复美
Approval Number
国药准字HJ20215003
Approval Date
Dec 7, 2023
NMPA

Lenalidomide capsules

Product Name
瑞复美
Approval Number
国药准字HJ20171348
Approval Date
Dec 7, 2023
NMPA

Lenalidomide capsules

Product Name
瑞复美
Approval Number
国药准字HJ20200047
Approval Date
Dec 7, 2023
NMPA

Lenalidomide capsules

Product Name
瑞复美
Approval Number
国药准字HJ20200046
Approval Date
Dec 7, 2023
NMPA

Lenalidomide capsules

Product Name
瑞复美
Approval Number
国药准字HJ20200048
Approval Date
Dec 7, 2023
NMPA

Nivolumab injection

Product Name
欧狄沃
Approval Number
国药准字SJ20180014
Approval Date
Mar 31, 2023
NMPA

Nivolumab injection

Product Name
欧狄沃
Approval Number
国药准字SJ20180015
Approval Date
Mar 31, 2023
NMPA

Ozanimod Hydrochloride Capsules

Product Name
热珀西亚
Approval Number
国药准字HJ20230004
Approval Date
Jan 31, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.